Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil;Recomendações do Departamento de Neuroendocrinologia da Sociedade Brasileira de Endocrinologia e Metabologia para o diagnóstico e tratamento da acromegalia no Brasil

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 55, Issue 2, 2011, Pages 91-105

  Neto, Leonardo Vieira ^a,b   Abucham, Julio ^c   de Araujo, Luiz Antônio ^d   Boguszewski, Cesar L ^e   Bronstein, Marcello D ^f   Czepielewski, Mauro ^g   Jallad, Raquel S ^f   Musolino, Nina R de C ^f   Naves, Luciana A ^h   Ribeiro Oliveira Jr , Antônio ⁱ   Vilar, Lucio ^j   Faria, Manuel dos S ^k   Gadelha, Mônica R ^a,l  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b HOSPITAL DA LAGOA   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Instituto de Endocrinologia de Joinville (IEJE/CAD)   (Brazil)

^e FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

^g HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^h HOSPITAL UNIVERSITÁRIO DE BRASÍLIA   (Brazil)

ⁱ FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^j FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

^k FEDERAL UNIVERSITY OF MARANHÃO   (Brazil)

^l Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

more..

Author keywords

Acromegaly; Diagnosis; Recommendations; Treatment

Indexed keywords

HUMAN GROWTH HORMONE;

ACROMEGALY; BRAZIL; HUMAN; PRACTICE GUIDELINE; REVIEW; SECRETION; SYNDROME;

ACROMEGALY; BRAZIL; HUMAN GROWTH HORMONE; HUMANS; SYNDROME;

EID: 79957584531     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/S0004-27302011000200001     Document Type: Review

References (62)

1. Donangelo I, Une K, Gadelha M. Diagnóstico e tratamento da acromegalia no Brasil. Arq Bras Endocrinol Metabol. 2003;47(4):331-46.
2. Vieira Neto L, Taboada GF, Correa LL, Polo J, Nascimento AF, Chimelli L, et al. Acromegaly secondary to growth hormone-releasing hormone secreted by an incidentally discovered pheochromocytoma. Endocr Pathol. 2007;18(1):46-52.
3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102-52.
4. Lima GA, Gomes EM, Nunes RC, Vieira Neto L, Sieiro AP, Brabo EP, et al. Osteosarcoma and acromegaly: a case report and review of the literature. J Endocrinol Invest. 2006;29(11):1006-11.
5. Casini AF, Araujo PB, Fontes R, Xavier SS, Gadelha MR. [Cardiac morphology and performance alterations and analysis of determinant factors of left ventricular hypertrophy in 40 patients with acromegaly]. Arq Bras Endocrinol Metabol. 2006;50(1):82-90.
6. Correa LL, Taboada GF, Van Haute FR, Casini AF, Balarini GA, Vieira Neto L, et al. [Evaluation of glucose metabolism in acromegalic patients before and after treatment with octreotide LAR]. Arq Bras Endocrinol Metabol. 2008;52(1):55-64.
7. Van Haute FR, Taboada GF, Correa LL, Lima GA, Fontes R, Riello AP, et al. Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging. Eur J Endocrinol. 2008;158(4):459-65.
8. Reid TJ, Post KD, Bruce JN, Nabi Kanibir M, Reyes-Vidal CM, Freda PU. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf). 2010;72(2):203-8.
9. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008;93(1):61-7.
10. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159(2):89-95.
11. Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004;89(2):667-74.
12. Leavitt J, Klein I, Kendricks F, Gavaler J, Van Thiel DH. Skin tags: a cutaneous marker for colonic polyps. Ann Intern Med. 1983;98(6):928-30.
13. Boguszewski CL. O laboratório no diagnóstico e seguimento da acromegalia. Arq Bras Endocrinol Metab. 2002;46(1):34-44.
14. Dimaraki EV, Jaffe CA, DeMott-Friberg R, Chandler WF, Barkan AL. Acromegaly with apparently normal GH secretion: implications for diagnosis and follow-up. J Clin Endocrinol Metab. 2002;87(8):3537-42.
15. Rosario PW. Normal values of serum IGF-1 in adults: results from a Brazilian population. Arq Bras Endocrinol Metabol. 2010;54(5):477-81.
16. Clemmons DR, Van Wyk JJ. Factors controlling blood concentration of somatomedin C. Clin Endocrinol Metab. 1984;13(1):113-43.
17. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85(2):526-9.
18. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95(7):3141-8.
19. Freda PU. Current concepts in the biochemical assessment of the patient with acromegaly. Growth Horm IGF Res. 2003;13(4):171-84.
20. Ribeiro-Oliveira Jr A, Faje AT, Barkan AL. Limited utility of oral glucose tolerance test in biochemically-active acromegaly. Eur J Endocrinol. 2011;164(1):17-22. Epub 2010 Oct 6.
21. Taboada GF, Correa LL, Oliveira Machado E, Van Haute FR, Casini AF, Balarini GA, et al. Two hour mean GH is not superior to basal GH for the follow-up of acromegalic patients treated with Octreotide LAR. Growth Horm IGF Res. 2007;17(1):77-81.
22. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009;94(5):1509-17.
23. Nomikos P, Buchfelder M, Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol. 2005;152(3):379-87.
24. Jallad RS, Musolino NR, Kodaira S, Cescato VA, Bronstein MD. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf). 2007;67(2):310-5.
25. Freda PU, Nuruzzaman AT, Reyes CM, Sundeen RE, Post KD. Significance of "abnormal" nadir growth hormone levels after oral glucose in postoperative patients with acromegaly in remission with normal insulin-like growth factor-I levels. J Clin Endocrinol Metab. 2004;89(2):495-500.
26. Fatemi N, Dusick JR, Mattozo C, McArthur DL, Cohan P, Boscardin J, et al. Pituitary hormonal loss and recovery after transsphenoidal adenoma removal. Neurosurgery. 2008;63(4):709-18; discussion 18-9.
27. Neto LV, Machado Ede O, Luque RM, Taboada GF, Marcondes JB, Chimelli LM, et al. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab. 2009;94(6):1931-7.
28. Jaffe CA, Barkan AL. Treatment of acromegaly with dopamine agonists. Endocrinol Metab Clin North Am. 1992;21(3):713-35.
29. Verhelst J, Abs R, Maiter D, Van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84(7):2518-22.
30. Abs R, Verhelst J, Maiter D, Van Acker K, Nobels F, Coolens JL, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83(2):374-8.
31. Vilar L, Czepielewsk MA, Naves LA, Rollin GA, Casulari LA, Coelho CE. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr Pract. 2007;13(4):396-402.
32. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29-38.
33. Lancellotti P, Livadariu E, Markov M, Daly AF, Burlacu MC, Betea D, et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur J Endocrinol. 2008;159(1):1-5.
34. Taboada GF, Luque RM, Neto LV, Machado Ede O, Sbaffi BC, Domingues RC, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol. 2008;158(3):295-303.
35. Vieira Neto L, Taboada GF, Gadelha MR. Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and gsp status as predictors of octreotide LAR responsiveness in acromegaly. Arq Bras Endocrinol Metabol. 2008;52(8):1288-95.
36. Freda PU, Katznelson L, Van der Lely AJ, Reyes CM, Zhao S, Rabinowitz D. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005;90(8):4465-73.
37. Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93(8):2957-68.
38. Jallad RS, Musolino NR, Salgado LR, Bronstein MD. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol (Oxf). 2005;63(2):168-75.
39. Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, et al. Primary treatment of acromegaly with octreotide LAR: a long--term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91(4):1397-403.
40. Cozzi R, Attanasio R, Lodrini S, Lasio G. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf). 2004;61(2):209-15.
41. Jallad RS, Bronstein MD. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide. Neuroendocrinology. 2009;90(1):82-92.
42. Vilar L, Azevedo MF, Naves LA, Casulari LA, Albuquerque JL, Montenegro RM, et al. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR. Pituitary. 2010 Nov 21.
43. Mattar P, Alves Martins MR, Abucham J. Short-and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf--I levels in acromegaly. Neuroendocrinology. 2010;92(2):120-7.
44. Machado EO, Taboada GF, Neto LV, Van Haute FR, Correa LL, Balarini GA, et al. Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR. Growth Horm IGF Res. 2008;18(5):389-93.
45. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002;87(7):3013-8.
46. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, Van der Lely AJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342(16):1171-7.
47. Van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet. 2001;358(9295):1754-9.
48. Marazuela M, Lucas T, Alvarez-Escola C, Puig-Domingo M, Garcia de la Torre N, Miguel-Novoa P, et al. Long-term treatment of acromegalic patients resistant to somatostatin analogs with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol. 2009;160(4):535-42. Epub 2009 Jan 15.
49. Jorgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LO, Hagen C, et al. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab. 2005;90(10):5627-31.
50. Feenstra J, De Herder WW, Ten Have SM, Van den Beld AW, Feelders RA, Janssen JA, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005;365(9471):1644-6.
51. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab. 2005;90(10):5684-91.
52. Neggers SJ, Van Aken MO, Janssen JA, Feelders RA, De Herder WW, Van der Lely AJ. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007;92(12):4598-601.
53. Roelfsema F, Biermasz NR, Pereira AM, Romijn JA. The role of pegvisomant in the treatment of acromegaly. Expert Opin Biol Ther. 2008;8(5):691-704.
54. Bernabeu I, Marazuela M, Lucas T, Loidi L, Alvarez-Escola C, Luque-Ramirez M, et al. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome. J Clin Endocrinol Metab. 2010;95(5):2147-54.
55. Buhk JH, Jung S, Psychogios MN, Goricke S, Hartz S, Schulz-Heise S, et al. Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab. 2010;95(2):552-8.
56. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S. Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab. 2008;93(9):3515-8.
57. Jaffe CA. Reevaluation of conventional pituitary irradiation in the therapy of acromegaly. Pituitary. 1999;2(1):55-62.
58. Peacey SR, Shalet SM. Growth hormone pulsatility in acromegaly following radiotherapy. Pituitary. 1999;2(1):63-9.
59. Barkan AL. Radiotherapy in acromegaly: the argument against. Clin Endocrinol (Oxf). 2003;58(2):132-5.
60. Brada M, Ford D, Ashley S, Bliss JM, Crowley S, Mason M, et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ. 1992;304(6838):1343-6.
61. Jackson IM, Noren G. Role of gamma knife therapy in the management of pituitary tumors. Endocrinol Metab Clin North Am. 1999;28(1):133-42.
62. Attanasio R, Epaminonda P, Motti E, Giugni E, Ventrella L, Cozzi R, et al. Gamma-knife radiosurgery in acromegaly: a 4-year follow--up study. J Clin Endocrinol Metab. 2003;88(7):3105-12.